Status:
COMPLETED
CeraVe Diabetes Mellitus
Lead Sponsor:
University of Miami
Collaborating Sponsors:
CeraVe
Conditions:
Diabetes Complications
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of the CeraVe Diabetic Skin Line for the improvement of skin condition in patients with diabetes mellitus.
Eligibility Criteria
Inclusion
- Men or women between the ages of 18 and 75 years of age.
- Willing to provide written informed consent.
- A diagnosis of diabetes mellitus (DM).
- DM-related skin changes classified into one or more of the following four categories: i) skin lesions associated with DM; ii) infections; iii) cutaneous manifestations of DM complications; iv) skin reaction to DM treatment.
Exclusion
- History of allergy, anaphylaxis or hypersensitivity to any of the ingredients in CeraVe Hydrating Cleanser or Moisturizing Cream
- History of allergic contact dermatitis secondary to cleansers or moisturizers.
- Has a heightened immune response to common allergens, especially inhaled, topical or food allergens (atopy).
- Has any clinical manifestation in the treatment are(s) or other disorders that, in the investigator's opinion, may affect assessments or the study products.
- Inability to attend all study visits and follow treatment regimen.
Key Trial Info
Start Date :
March 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 10 2021
Estimated Enrollment :
528 Patients enrolled
Trial Details
Trial ID
NCT04724967
Start Date
March 12 2021
End Date
August 10 2021
Last Update
September 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136